

Cellular Tumor Antigen p53 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/CE2EF54FB4B3EN.html>

Date: December 2019

Pages: 134

Price: US\$ 3,500.00 (Single User License)

ID: CE2EF54FB4B3EN

Abstracts

Cellular Tumor Antigen p53 - Pipeline Review, H2 2019

SUMMARY

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) pipeline Target constitutes close to 27 molecules. Out of which approximately 25 molecules are developed by companies and remaining by the universities/institutes. The latest report Cellular Tumor Antigen p53 - Pipeline Review, H2 2019, outlays comprehensive information on the Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Tumor protein p53 also known as p53 is any isoform of a protein encoded by TP53 gene. TP53 gene is the most frequently mutated gene in human cancer indicating that the TP53 gene plays a crucial role in preventing cancer formation. Activated p53 binds DNA and activates expression of several genes including microRNA miR-34a, WAF1/CIP1 encoding for p21 and hundreds of other down-stream genes. p21 binds to the G1-S/CDK (CDK4/CDK6, CDK2, and CDK1) complexes (molecules important for the G1/S transition in the cell cycle) inhibiting their activity.

The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 7, 2, 7, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Dermatology, Genito Urinary System And Sex Hormones, Immunology and Toxicology which include indications Colorectal Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Ovarian

Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Small-Cell Lung Cancer, Solid Tumor, Esophageal Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Pancreatic Cancer, Myelodysplastic Syndrome, Pancreatic Cancer, Prostate Cancer, Triple-Negative Breast Cancer (TNBC), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Renal Failure (ARF) (Acute Kidney Injury), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Alopecia, Anaplastic Astrocytoma, Bladder Cancer, Blood Cancer, Brain Cancer, Brain Tumor, Central Nervous System (CNS) Tumor, Cervical Cancer, Chemotherapy Effects, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Delayed Graft Function (DGF), Endometrial Cancer, Gastrointestinal Tumor, Gliosarcoma, Hepatic - Colorectal Metastasis, Hepatocellular Carcinoma, Leukemia, Li-Fraumeni Syndrome (LFS), Lung Cancer, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Multiple Myeloma (Kahler Disease), Neuroendocrine Tumors, Oligodendroglioma, Pediatric Diffuse Intrinsic Pontine Glioma, Primitive Neuroectodermal Tumor (PNET), Recurrent Glioblastoma Multiforme (GBM), Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Recurrent Medulloblastoma, Refractory Medulloblastoma, Renal Cell Carcinoma, Retinoblastoma, Soft Tissue Sarcoma and Urinary Tract Cancer.

Furthermore, this report also reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)

The report reviews Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics and enlists all their major and minor projects

The report assesses Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading

companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Overview

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Companies Involved in Therapeutics Development

Actavalon Inc

ADRx Inc

Affina Biotechnologies Inc

Aprea Therapeutics AB

BlinkBio Inc

CanBas Co Ltd

Cotinga Pharmaceuticals Inc

Innovation Pharmaceuticals Inc

ISA Pharmaceuticals BV

LynkCell Inc

MultiVir Inc

ORCA Therapeutics BV

OSE Immunotherapeutics

Pharos I&BT Co Ltd

PMV Pharmaceuticals Inc

Quark Pharmaceuticals Inc

Shenzen SiBiono GeneTech Co Ltd

SynerGene Therapeutics Inc

Tara Immuno-Oncology Therapeutics LLC

Z53 Therapeutics LLC

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Drug Profiles

Adp-53DCV - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APR-246 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

APR-548 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AU-14022 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

contusogene ladenovec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

COTI-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Dormant Products

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Discontinued Products

Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Actavalon Inc, H2 2019
Pipeline by ADRx Inc, H2 2019
Pipeline by Affina Biotechnologies Inc, H2 2019
Pipeline by Aprea Therapeutics AB, H2 2019
Pipeline by BlinkBio Inc, H2 2019
Pipeline by CanBas Co Ltd, H2 2019
Pipeline by Cotinga Pharmaceuticals Inc, H2 2019
Pipeline by Innovation Pharmaceuticals Inc, H2 2019
Pipeline by ISA Pharmaceuticals BV, H2 2019
Pipeline by LynkCell Inc, H2 2019
Pipeline by MultiVir Inc, H2 2019
Pipeline by ORCA Therapeutics BV, H2 2019
Pipeline by OSE Immunotherapeutics, H2 2019
Pipeline by Pharos I&BT Co Ltd, H2 2019
Pipeline by PMV Pharmaceuticals Inc, H2 2019
Pipeline by Quark Pharmaceuticals Inc, H2 2019
Pipeline by Shenzhen SiBiono GeneTech Co Ltd, H2 2019

Pipeline by SynerGene Therapeutics Inc, H2 2019

Pipeline by Tara Immuno-Oncology Therapeutics LLC, H2 2019

Pipeline by Z53 Therapeutics LLC, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Dormant Products, H2 2019 (Contd..2), H2 2019

Dormant Products, H2 2019 (Contd..3), H2 2019

Dormant Products, H2 2019 (Contd..4), H2 2019

Dormant Products, H2 2019 (Contd..5), H2 2019

Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Actavalon Inc

ADRx Inc

Affina Biotechnologies Inc

Aprea Therapeutics AB

BlinkBio Inc

CanBas Co Ltd

Cotinga Pharmaceuticals Inc

Innovation Pharmaceuticals Inc

ISA Pharmaceuticals BV

LynkCell Inc

MultiVir Inc

ORCA Therapeutics BV

OSE Immunotherapeutics

Pharos I&BT Co Ltd

PMV Pharmaceuticals Inc

Quark Pharmaceuticals Inc

Shenzen SiBiono GeneTech Co Ltd

SynerGene Therapeutics Inc

Tara Immuno-Oncology Therapeutics LLC

Z53 Therapeutics LLC

I would like to order

Product name: Cellular Tumor Antigen p53 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/CE2EF54FB4B3EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CE2EF54FB4B3EN.html>